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The onset of pregnancy implies the appearance of a new organ, the placenta. One main
function of the placenta is to supply oxygen to the fetus via hemoproteins. In this review,
we highlight the importance of the enzyme heme oxygenase-1 (HO-1) for pregnancy to
be established and maintained. HO-1 expression is pivotal to promote placental function
and fetal development, thus determining the success of pregnancy. The deletion of the
gene Hmox1 in mice leads to inadequate remodeling of spiral arteries and suboptimal
placentation followed by intrauterine growth restriction (IUGR) and fetal lethality. A partial
Hmox1 deletion leads to IUGR as well, with heterozygote and wild-type fetuses being born,
but Hmox1−/− significantly below the expected Mendelian rate. This strong phenotype is
associated with diminished number of pregnancy-protective uterine natural killer (uNK)
cells. Pregnant heterozygote females develop gestational hypertension. The protective
HO-1 effects on placentation and fetal growth can be mimicked by the exogenous
administration of carbon monoxide (CO), a product of heme catalyzed by HO-1. CO
application promotes the in situ proliferation of uNK cells, restores placentation and fetal
growth, while normalizing blood pressure. Similarly, HO-1 inhibition provokes hypertension
in pregnant rats. The HO-1/CO axis plays a pivotal role in sustaining pregnancy and aids
in the understanding of the biology of pregnancy and reveals a promising therapeutic
application in the treatment of pregnancy complications.
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INTRODUCTION
Heme oxygenase-1 (HO-1) catalyzes the first and rate-limiting
step in heme catabolism toward biliverdin, carbon monoxide
(CO), and free iron (Tenhunen et al., 1968). HO-1 represents
the stress-responsive HO isoform and is encoded by the Hmox1
gene. As shown in vitro and in vivo studies, HO-1 is cytopro-
tective and exerts anti-inflammatory effects, while regulating cell
proliferation (Soares et al., 1998; Otterbein et al., 2000; Duckers
et al., 2001; Soares and Bach, 2009). HO-1 not only prevents
tissue injury; but also, modulates innate and adaptive immune
responses (Duckers et al., 2001). Thus, HO-1 is a central player in
suppressing the pathogenesis of immune-mediated inflammatory
diseases (Soares et al., 2009). The cytoprotective and immunoreg-
ulatory effects of HO-1 no longer exist after the pharmacological
inhibition of its enzymatic activity. The exogenous application
of CO by inhalation is able to restore the cytoprotective effects
HO-1 (Brouard et al., 2000; Otterbein et al., 2000; Ryter et al.,
2002). Hence, CO mediates, to a large extent, the salutary effects
of HO-1. However, other products of heme catabolism such as
iron and biliverdin, might act in a similar manner. In this review,
we will focus on the protective effects of HO-1 and its main
metabolite CO.
HO-1 EXPRESSION IN FEMALE REPRODUCTIVE ORGANS
Alexandreanu and Lawson (2003) reported that rat theca cells,
granulosa cells of follicles, and luteal cells stain positively for
HO-1; whereas, ovarian stromal cells have a low intensity of stain-
ing. They further showed that three daily injections of the HO-1
inducer hemin stimulated basal- and gonadotropin-induced
androstenedione and estradiol secretion from ovaries of imma-
ture rats treated with pregnant mare serum gonadotropin in vitro,
but had no effect on progesterone production (Alexandreanu
and Lawson, 2003). Thus, HO-1 is present in the rat ovary and
may be involved in the production of ovarian steroids. In mice,
HO-1 is expressed in the ovaries and HO-1-deficient mice have
deficient ovulation (Zenclussen et al., 2012). Contrary to the data
obtained in the rat, variations in HO-1 did not influence the
production of female hormones in the mouse (Zenclussen et al.,
2011). However, estrous cycle-related changes in hormonal levels
significantly modified the temporal expression of HO-1 in uterine
cells (Zenclussen et al., 2014).
Upon fecundation, HO-1 is expressed very early in preg-
nancy. Already at the blastocyst stage, its presence determines the
attaching ability of blastocysts to uterine epithelial cells (UECs;
Zenclussen et al., 2011). As this stage is determinant for the
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implantation success, the absence of HO-1 implies a deficient or
absence of implantation.
HO-1 is expressed in trophoblasts as shown in human studies
(Acevedo and Ahmed, 1998; Ahmed et al., 2000; Lyall et al., 2000;
McLean et al., 2000; Zenclussen et al., 2003), mice (Zenclussen
et al., 2005, 2006; Zhang et al., 2007; Tachibana et al., 2008) and
rat (Ihara et al., 1998; Kreiser et al., 2002) placentas. There is a
consensus that HO-1 expression in trophoblasts is indicative of
adequate placental development and fetal well-being. It is highly
induced during human, rat, and mouse pregnancies, namely in
placental trophoblasts (Barber et al., 2001; Zenclussen et al.,
2003; Sollwedel et al., 2005). HO-1 induction supports pregnancy,
diminishing the early onset of murine abortions (Sollwedel et al.,
2005; Zenclussen et al., 2006). Reduced HO-1 levels are associated
with human miscarriages and murine fetal losses (Zenclussen
et al., 2003, 2005; Sollwedel et al., 2005) and pre-eclampsia,
the most severe pathological complication of pregnancy (Ahmed
et al., 2000).
Due to its continual presence at all stages of the reproductive
cycle and during pregnancy, HO-1 is believed to play a central
regulatory role in reproduction. In fact, there are limited examples
of genes whose expression is strictly required at multiple stages of
pregnancy in mammals (Wang and Dey, 2006).
Very few Hmox1 null (Hmox1−/−) mice, obtained by mat-
ing Hmox1+/− mice, survive to adulthood. Surviving Hmox1−/−
female mice were initially wrongly reported as infertile (Poss and
Tonegawa, 1997; Yet et al., 1999; Tzima et al., 2009). Now we know
that HO-1 knockout female are not infertile, but their gestations
jeopardized due to the fact that the majority of their fetuses die
in utero (Zenclussen et al., 2011). Hence, HO-1 emerges as a
key molecule that regulates not one, but many, steps of female
reproduction.
HO-1 CONTRIBUTES TO OVULATION AND FERTILIZATION
The requirement of iron in adult life is around 4–5 mg daily
(Andrews and Schmidt, 2007). The most common form is the
reduced ferrous Fe2+ iron complexed with the two α-globin
and two β-globin chains of heme to form hemoglobin. When
red blood cells (RBCs) are lysed, iron is usually oxidized and
heme no longer binds to hemoglobin, and is released as free
heme. If left uncontrolled, free heme and oxidized iron can be
harmful; both possessing pro-inflammatory, pro-oxidant, and
tissue damaging properties (Soares and Bach, 2009). Free heme
can be catabolized by HO-1. Insufficient iron uptake is related
to subfertility. Women who consumed iron supplements had
a significantly lower risk of ovulatory infertility than women
who did not use iron supplements. Total non-heme iron intake,
primarily consumed as multivitamins and iron supplements, was
inversely associated with the risk of infertility. However, iron
intake was unrelated to ovulatory infertility in multivariable-
adjusted analyses (Chavarro et al., 2006). In rabbits, Lindahl et al.
(1984) investigated the effect of ovulation on heme metabolism.
HO activity, measured as total excretion of endogenous CO, was
not increased after administration of any precursor for heme
synthesis. However, CO increased 34% during the post-ovulation
period. Because the increase in heme turnover after stimulation
was small and may be unaccompanied by a contemporary increase
in bilirubin/CO production, it was concluded that this increase in
CO essentially was due to an increased destruction of circulating
RBCs in the rabbit (Lindahl et al., 1984). For this step, elevated
amounts of HO-1 are needed. Recently, we performed a mouse
study designed to elucidate whether HO-1 is required for the
process of oocyte production (ovulation) and subsequent corpus
luteum (CL) formation. Thus, we documented the number of
oocytes produced by Hmox1 null mice compared to Hmox1
wild-type (Wt) mice after pregnant mare serum gonadotropin
(PMSG) plus human chorionic gonadotropin (hCG) hormonal
stimulation. We observed that Hmox1 null females produced
significantly lower numbers of oocytes compared to Hmox1 Wt
mice in response to hormonal stimulation, clearly supporting a
role for HO-1 in the process of ovulation (Zenclussen et al., 2012).
We also analyzed how effectively these oocytes could be fertilized
despite less oocytes were retrieved after hormonal stimulation.
The fertilization rate of Hmox1 null oocytes with sperm from
knockout males was dramatically reduced as compared to Wt
oocytes fertilized by Wt sperm. As sperm from Hmox1+/+ and
Hmox1−/− are equally fertile, it is clear that HO-1 expression
in the oocytes modifies the ability of oocytes to be fertilized
(Zenclussen et al., 2012). The total number of follicles was similar
in both groups and the follicle composition was also comparable
(Zenclussen et al., 2012). The number of CL was, however, signif-
icantly lower in Hmox1 null than Wt mice, this being consistent
with the lower number of ovulated oocytes from HO-1-deficient
mice. Augmented apoptosis in the ovary of Hmox1 null animals
explained the lower number of CL (Zenclussen et al., 2012). After
ovulation, immune cells, mostly macrophages and eosinophils,
are located in the luteinizing theca area in the developing CL. This
highlights the inflammatory nature of this process. The presence
of HO-1 may represent one important counteracting mechanism
to inflammation. In fact, this enzyme may confer cytoprotection
during the inflammatory process of follicular rupture (Richards
et al., 2002). Expression of HO-1 would then be required to
prevent the cytotoxic effects of accumulated free heme. We pro-
posed that the lack of HO-1 causes mature follicles to die as they
are no longer protected from massive inflammation; hence, they
will not ovulate (Zenclussen et al., 2012). Hence, HO-1 supports
ovulation and the maintenance of the CL. Blastocyst attachment
to the pregnant uterus occurs in a narrow period of time after
fertilization called the “implantation window,” which is finely
regulated by hormones released by the CL (van Mourik et al.,
2009). As the proper on-time attachment of the blastocysts to the
uterine wall has profound implications on posterior implantation
and placentation (Song et al., 2002), the lack of HO-1 negatively
impacts pregnancy outcomes as depicted by the lower number
of and/or non-functional CL in mice whose HO-1 was ablated
(Zenclussen et al., 2012).
The expression of HO-1 during the cycle seems to be reg-
ulated by hormones. It was reported that variations in HO-1
expression in the uterus correlate with changes in hormones at
the four phases of the estrus cycle (Zenclussen et al., 2014).
Interestingly, HO-1 protein expression is highest when female
mice are receptive. In vitro, a combination of progesterone and
estradiol can stimulate the expression of HO-1 in AN3 uter-
ine cells (Zenclussen et al., 2014). Thus, hormones positively
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modulate HO-1 expression during receptivity, a crucial process
for later implantation of the blastocyst.
HO-1 CONTRIBUTES TO IMPLANTATION
Implantation is the earliest stage of pregnancy and is initiated
when the blastocyst adheres to the wall of the uterus. Differ-
ent processes take place during implantation. First, during the
so-called “hatching,” the blastocyst gets rid of its zona pellu-
cida. Immediately after, apposition takes place, which gener-
ates the very first connection between the blastocyst and the
endometrium. In the following step, the adhesion is a much
stronger attachment of the blastocyst to the endometrium. The
first trophoblast begins penetrating the endometrium and this is,
as mentioned before, a very aggressive and inflammatory process.
The communication between the blastocyst and the endometrium
at this stage is very intense. The blastocyst itself signals to the
endometrium to adapt to its presence and is therefore the premise
for correct invasion of the blastocyst into the endometrium and
subsequent remodeling of tissues and spiral arteries.
The study of implantation mechanisms in the human is very
difficult even though there are very elegant in vitro models. In
Carlos Simón’s laboratory, a heterologous implantation model
is used to study the ability of day 2 mouse embryos to attach
to human endometrial epithelial cells (Garrido-Gomez et al.,
2012; Vilella et al., 2013). Implantation in the mouse is very
similar to humans. To understand the participation of HO-1 in
implantation, we designed an in vitro mouse model to follow
the hatching and invasion of the murine blastocyst into UECs
grown in a stromal cell layer (Zenclussen et al., 2011). For this,
we isolated and grew UECs in a layer of homologous stromal
cells derived from either Hmox1-deficient or -sufficient animals
at 3.5 day of pregnancy. From the same animals, we obtained
blastocysts that were placed onto the UECs. With this model, we
were able to observe that Hmox1+/+ blastocysts attached signifi-
cantly faster than Hmox1+/− or Hmox1−/− blastocysts. Hmox1−/−
blastocysts failed to attach at all to UECs, which was not the
case for Hmox1+/+, which were all attached at 72 h (Zenclussen
et al., 2011). Evidently, HO-1 is expressed at the fetomaternal
interface as early as at blastocyst implantation (Zenclussen et al.,
2011). While not absolutely essential for implantation to occur,
HO-1 supports timely blastocyst attachment to UECs in vitro
(Zenclussen et al., 2011). Delayed implantation is known to
have a profound impact on placentation and fetal growth (Song
et al., 2002). In vivo, we could confirm that the size areas of
whole Hmox1+/− and Hmox1−/− fetoplacental units were sig-
nificantly smaller in contrast to whole Hmox1+/+ fetoplacental
units already at gestational age day 8 (Linzke et al., 2014). This
clearly means that the retarded attachment of the blastocyst to the
UECs has serious consequences on the dynamics of implantation
and thus on fetal growth. Chen et al. (2005) have identified
genes that are expressed at a high level in hatched human blas-
tocysts compared to pre-hatched blastocysts. Very interestingly,
these hatching-specific genes were expressed at lower levels in
the delayed growth embryos. Among the identified genes, HO-
1 attracted our interest (Chen et al., 2005). Thus, it seems that
also in humans, HO-1 is a crucial factor defining implantation
success.
HO-1 CONTRIBUTES TO PLACENTATION
It was reported by many research groups including ours that
human invasive trophoblasts express HO-1 (Acevedo and Ahmed,
1998; Ahmed et al., 2000; Lyall et al., 2000). Murine invasive
trophoblasts have typical giant cells (GC) morphological features,
namely large-sized polyploid cells. GCs are the first cells from the
ectoplacental clone to emerge and are critically involved in placen-
tation. To study how HO-1 expression contributes to trophoblast
physiology, we tested in vitro whether HO-1 is required for
trophoblast proliferation or modulation of trophoblastic stem cell
differentiation into GCs. For this, we employed the trophoblastic
rat stem cell line Rcho-1 that can be induced to differentiate
to GCs under determined conditions (Faria and Soares, 1991).
Inhibition of HO-1 was achieved by the application of zinc
protoporphyrin IX (ZnPP) and controls were treated with cobalt
protoporphyrin IX (CoPP) that did not modify HO-1 expression.
We observed that HO-1 inhibition reduced trophoblastic stem
cell viability drastically (Zenclussen et al., 2011). We next differ-
entiated stem cells into GCs and observed no changes in HO-1
expression during this process. The inhibition of HO-1 activity by
ZnPP, however, suppressed trophoblastic stem cell differentiation
into GCs, an effect not observed using CoPP. Thus, trophoblastic
stem cells that express HO-1 can differentiate into GCs while
cells lacking HO-1 cannot (Zenclussen et al., 2011). Hence, HO
activity regulates both, trophoblast survival and differentiation
into a mature phenotype, hence contributing importantly to pla-
centation. Similarly, inhibition of HO-1 expression using siRNA
inhibited viability of human primary trophoblasts isolated from
first trimester pregnancies (Zenclussen et al., 2011).
Newby et al. (2005) analyzed HO-1 expression in human
trophoblast cell cultures following exposure to different oxygen
environments. They observed that HO-1 expression was stronger
in cytotrophoblasts than in syncytiotrophoblasts. There was no
difference in HO-1 expression in cytotrophoblasts transferred to
low oxygen culture conditions. However, exposure of syncytiotro-
phoblast cultures to hypoxia for 12 h resulted in a significant
reduction in HO-1 (42). Contradicting these results, Appleton
et al. (2003b) tested HO-1 protein expression and enzymatic func-
tion in immortalized HTR-8/SVneo first-trimester trophoblast
cells and explants of normal human chorionic villi from term
placentas. They reported that HO-1 protein content was not
affected by changes in oxygenation. They used 24-h exposures to
1, 5, or 20% oxygen (Appleton et al., 2003b). The same authors
reported later that it is the combination of low oxygen and low
glucose concentrations that decreased the HO-1 protein (Apple-
ton et al., 2003a). Thus, it seems that in mice and humans, HO-1 is
expressed in trophoblasts and plays an important regulatory role
in its physiology.
The final confirmation that HO-1 is important for placenta-
tion was provided by mouse studies performed by Zhao et al.
(2009) and our group. First, Zhao et al. (2009) showed that
when Hmox1+/−mice were cross-bred (FvB background), placen-
tas and fetuses from Hmox1+/− cross-breedings were altogether
smaller and lighter than those from Wt cross-breedings. Shortly
after, we analyzed the histopathology of placentas obtained
from Hmox1+/+ × Hmox1+/+, Hmox1+/− × Hmox1+/−, and
Hmox1+/− × Hmox1−/− combinations (BALB/c background)
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after genotyping their respective embryos. We observed that
the number of GCs in placentas totally or partially deficient in
Hmox1 was significantly reduced as compared to Wt (Hmox1+/+)
placentas. In addition, Hmox1+/− and Hmox1−/− placentas
had enlarged labyrinth areas and reduced or absent junctional
areas with detectable morphological abnormalities, confirming
improper placentation. They further presented areas of fibrosis
and hemorrhage (Zenclussen et al., 2011). Thus, deletion of
the Hmox1 allele leads to abnormal placentation and likely to
insufficient nutrient and oxygen supply to the fetus. When mat-
ing Hmox1+/− with Hmox1+/−, there were no viable Hmox1−/−
fetuses detectable at day 12; while Hmox1+/− were significantly
much smaller than Hmox1+/+ ones. Impressively, most fetuses
from Hmox1−/− × Hmox1−/− combinations were non-viable
at day 14. These observations provide conclusive evidence that
deletion of the Hmox1 allele has major pathological consequences
during pregnancy leading to abnormal placentation, intrauterine
growth restriction (IUGR), and eventually to fetal loss (Zen-
clussen et al., 2011). Remarkably, numerous studies have reported
that HO-1 is diminished in cases of pre-eclampsia and IUGR
(Ahmed et al., 2000; Lyall et al., 2000; Zenclussen et al., 2003).
HO-1 CONTRIBUTES TO SPIRAL ARTERY DEVELOPMENT
Pregnancy success very much depends on adequate placentation
to ensure proper oxygen and nutrient supplies to the develop-
ing fetus. Uteroplacental blood flow increases dramatically dur-
ing gestation, this being facilitated by the growth and remodeling
of the maternal uterine spiral artery (SA) system. It is widely
demonstrated that insufficient uterine vascular remodeling leads
to pregnancy-associated pathologies like IUGR and pre-eclampsia
(Bewley et al., 1991; Bernstein et al., 1998). We recently showed
that the expression of angiogenic factors was diminished at the
fetomaternal interface of Hmox1−/− and Hmox1+/− implanta-
tions when compared to Hmox1+/+ implantations at gestational
days 8, 10, and 12. This was associated with lower numbers of
uNK cells, which is discussed below. These cells are necessary for
the correct SA remodeling. Therefore, we studied whether HO-1
contributed not only to diminished expression of angiogenic fac-
tors; but also, and more relevantly to disturbances in SA remodel-
ing. We found that at days 10 and 12 of pregnancy, SA remodeling
was dramatically impaired in Hmox1+/− and Hmox1−/− implan-
tation sites when compared to Hmox1+/+ controls (Linzke et al.,
2014). The ratio of wall to lumen diameter of the SA was sig-
nificantly increased in Hmox1+/− and Hmox1−/− implantations
compared to Wt implantations (Linzke et al., 2014). A thicker
wall and thus, a smaller lumen, means a restricted blood supply
to the fetus, which can have fatal consequences on its growth. In
fact, we observed that Hmox1+/− and Hmox1−/− concepti were
either severely growth retarded or suffered intrauterine deaths
(Zenclussen et al., 2011; Linzke et al., 2014). Wong and colleagues
also showed that a partial deficiency in HO-1 resulted in smaller
babies (Zhao et al., 2009). To confirm that the insufficient HO-
1 levels are directly related to the inadequate SA remodeling, we
treated Hmox1-deficient animals with the HO metabolite CO.
CO could not only normalize the number of uNKs and the
expression of angiogenic factors, but impressively restored SA
remodeling (Linzke et al., 2014). Thus, the expression of HO-1
at the fetomaternal interface is indispensable for optimal SA
remodeling that, in turn, ensures the timely growth of the fetus.
This is in agreement with data from human pregnancies. Several
authors showed that HO-1 is diminished at the fetomaternal
interface of patients with normotensive IUGR or pre-eclampsia
when compared to age-matched controls (Ahmed et al., 2000;
Lyall et al., 2000; Zenclussen et al., 2003). In these particular preg-
nancy complications, a suboptimal SA remodeling was described
(Bernstein et al., 1998).
HO-1 CONTRIBUTES TO BLOOD PRESSURE REGULATION
DURING PREGNANCY
If SA remodeling is not optimal, the maternal body will attempt to
supply the fetus with more blood, which can lead to hypertension.
It therefore can be expected that a suboptimal SA remodeling due
to HO-1 deficiency is associated with increased blood pressure.
We recently showed that HO-1 deficiency altered the number
of uNKs, their angiogenic factors secreted, and negatively inter-
fered with SA remodeling, thus resulting in IUGR. But most
importantly, we could show that HO-1-deficient females devel-
oped hypertension beginning at day 14 of pregnancy (Linzke
et al., 2014). Hypertension is thought to be a consequence of
an insufficient blood supply to the fetus following impaired SA
remodeling (Robson et al., 2012). Thus, animals deficient in HO-
1 resemble a model of naturally-occurring pre-eclampsia (Linzke
et al., 2014). These findings are complemented by previous studies
from Zhao et al. (2009) who showed an increase in diastolic
blood pressure in pregnant HO-1-deficient mice. In the same
line of evidence, George et al. (2013) showed that the treatment
of pregnant rats with the HO-1 inhibitor tin mesoporphyrin
(SnMP) provoked gestational hypertension. In response to SnMP
treatment, maternal arterial pressure not only increased; but also,
placental VEGF was decreased (George et al., 2013). In a rat model
in which hypertension was induced by continuous infusion of
recombinant sFlt-1, George et al. (2011) could show that the
HO-1 induction after application of CoPPIX helped normalize
blood pressure. The mechanisms behind this were not investi-
gated and are unclear, especially because neither our group nor
George and colleagues could find a correlation between HO-1
and sFlt-1 (George et al., 2013; Linzke et al., 2014). However, at
least one other paper reported that in vitro, HO-1 and/or CO
downregulated sFlt-1 production (Cudmore et al., 2007). The role
of HO-1 in preventing gestational hypertension was confirmed
after observing that CO application during days 3–8 could com-
pensate for HO-1 deficiency and reversed the development of
hypertension and IUGR in a mouse model (Linzke et al., 2014).
Cigarette smoking during pregnancy is obviously a non-healthy
habit that is associated with adverse maternal, placental, and
fetal effects, e.g., preterm-delivery, abnormal placentation and
small-for-gestational age (SGA) fetuses (Bainbridge et al., 2005).
However, women smoking cigarettes during pregnancy have a
reduced risk developing pre-eclampsia (Conde-Agudelo et al.,
1999; England and Zhang, 2007). One mechanism through which
cigarette smoke may decrease the risk of developing pre-eclampsia
in pregnancy is the essential element CO (Zhai et al., 2012), while
the other cigarette components may account for the negative
effects. This warrants further investigation. It is important to
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remark that both, dose and time of exposure to CO are very
important. To achieve positive effects on gestational hypertension
was achieved at very low doses of 50 ppm during the process
of periimplantation (days 3–8 of pregnancy). Higher doses were
detrimental while shorter time exposures had no relevant effect
(El-Mousleh et al., 2012). We showed that CO application during
early mouse pregnancy could actually prevent hypertension and
IUGR (Linzke et al., 2014). CO therapy should be explored in
more detail, especially after the recent report on decreased risk
of pre-eclampsia after maternal exposure to moderate ambient
CO (Zhai et al., 2012). In animals that spontaneously develop
pre-eclampsia, hypertension was first detectable at day 14, while
CO application prevented this only if applied from day 3 to
day 8 of pregnancy (Linzke et al., 2014). It is clear then that
the events leading to pre-eclampsia development are triggered
and can be corrected beginning as early as day 3. In humans, a
shallow invasion of the trophoblast at week 14, long before pre-
eclamptic symptoms arise, is responsible for the pathophysiology
of this complex disease (Redman and Sargent, 2005). We previ-
ously proposed that the excess of free heme in Hmox1+/− ani-
mals contributes in part to gestational hypertension (Zenclussen
et al., 2011). These animals are not hypertensive before or at the
beginning of pregnancy. However, as pregnancy advances and the
circulating blood volume increases, low levels of HO-1 are not
enough to remove the excessive free heme, known to be cyto-
toxic. It was shown that pre-eclamptic placentas that express less
HO-1 also had a reduced phosphorylation of phosphoinositide
kinase (PI3K)/Akt, and this correlated with the elevated levels of
circulating sEng. In trophoblasts, knockdown of Akt prevented
HO-1-mediated inhibition of sEng release and reduced HO-
1 expression. Accordingly, non-pregnant Hmo1 null mice had
reduced phosphorylated Akt in their organs and overexpression
of Akt(myr) failed to suppress the elevated levels of sEng detected
in HO-1 null mice, indicating that HO-1 is required for the
Akt-mediated inhibition of sEng (Cudmore et al., 2012). Thus,
it seems possible that the loss of PI3K/Akt and/or HO activity
promotes sEng release; positive manipulation of these pathways
may offer a strategy to circumvent endothelial dysfunction.
HO-1 PARTICIPATION DURING PREGNANCIES JEOPARDIZED
BY INFECTIONS
Because of its central role in preventing inflammation, HO-1
may be also important in pregnancies that are in danger because
of the presence of pathogens. Recently, Penha-Goncalves et al.
(2014) proposed an important role for HO-1 during gestational
malaria. In fact, plasmodium infection during gestation is related
to severe clinical manifestations including abortion and stillbirth.
In a mice model of severe placental malaria (after infection with
Plasmodium berghei), both mothers and fetuses often succumb
to infection before or immediately after delivery (Mineo et al.,
2013). P. berghei-infected erythrocytes accumulate in the placenta,
where they are then phagocytized by trophoblasts (de Moraes
et al., 2013; Lima et al., 2014). Inside the phagosomes, disruption
of the RBCs provokes the release of free heme, which has to be
catabolized by HO-1. Results of Penha-Goncalves et al.’s (2014)
studies suggest that free heme-derived iron overload in infected
trophoblasts leads to fetal death. Only placentas with no visible
iron accumulation could support the normal growth of fetuses.
Thus, increased HO activity would protect fetuses from injury.
Accordingly, Woudwyk et al. (2012) showed that pregnant BALB/c
female mice that have been infected with Tritrichomonas foetus
had strongly decreased levels of HO-1 in those concepti that
died immediately after infections. In a study by Tachibana et al.
(2011), it could be showed that Listeria monocytogenes infection
in trophoblast GCs decreased HO-1 and Bcl-XL. Their upreg-
ulation, however, inhibited cell death induced by the infection.
Accordingly, HO-1 and Bcl-XL expression levels were decreased
after L. monocytogenes infection of pregnant mice. Treatment with
CoPP inhibited infectious abortion (Tachibana et al., 2011). This
goes hand in hand with the protective effects of both HO-1-based
gene therapy and CoPPIX application in pregnancies (Sollwedel
et al., 2005; Zenclussen et al., 2006). Similarly, in a model of
Brucella abortus, it was shown that the expression of HO-1 in the
placenta was decreased by B. abortus infection (Tachibana et al.,
2008). Again, CoPPIX was able to inhibit abortions due to the
bacterial infection (Tachibana et al., 2008). Thus, HO-1 emerges
as a protective mechanism in placental cells, in charge of keeping
the tissue under surveillance in order to avoid inflammatory
consequences that can lead to embryonic or fetal death.
MECHANISMS BEHIND THE PROTECTIVE EFFECTS OF HO-1
IN PREGNANCY
In recent years, key evidences emerged showing that HO-1 is
essential for many steps of pregnancy. It is therefore of vital
importance to understand the mechanisms underlying the pro-
tective effects of HO-1. The mechanisms may vary depending
on the reproductive phase HO-1 with which is involved. The
microenvironment where HO-1 action is required may also have
a significant influence on the mechanisms activated. The best
study mechanism underlying HO-1 effects that may account for
several of its positive gestational effects is the release of CO.
This accounts not only for reproductive processes (Cudmore
et al., 2007; Zenclussen et al., 2011; El-Mousleh et al., 2012;
Linzke et al., 2014); but also, for many inflammatory processes
(Gozzelino et al., 2010; Wegiel et al., 2014a,b). Already at the
trophoblast stage, we observed that the application of CO could
overcome the negative effects of ZnPP treatment to trophoblast
stem cells and enable their proliferation and further conversion
into GCs (Zenclussen et al., 2011). Similarly, the addition of CO
to cultured human trophoblasts from patients with pre-eclampsia
diminished their ability to secrete sFlt-1 (Cudmore et al., 2007).
Free heme per se is sufficient to precipitate intrauterine fetal
deaths in Wt Hmox1+/+ mice, and this is independent of the
maternal adaptive immune system (Zenclussen et al., 2011). It
can, however, be suppressed by the administration of low doses
of CO. Indeed, exogenous CO applied between pre-implantation
until placentation prevents fetal loss in Hmox1+/− females mated
with Hmox1+/− males as compared to air-treated controls. More
importantly, CO can rescue Hmox1−/− fetuses that die otherwise
in utero (Zenclussen et al., 2011). The protective effect of CO was
associated primarily with the normalization of placenta morphol-
ogy (Zenclussen et al., 2011). In further studies, we showed that
the prevention of fetal deaths by CO might be due to both the pre-
vention of free heme deposition and the augmentation in the uNK
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cell numbers (Linzke et al., 2014). uNK cells contribute to the
invasion of trophoblast cells in early pregnancy. Insufficient uNK
cell activation in early pregnancy leads to an imbalance in vascular
formation and this may cause the onset of pre-eclampsia in late
pregnancy. HO-1-deficient mice have reduced uNK cell numbers
and develop hypertension at mid- to late pregnancy (Linzke
et al., 2014). From our published results, we propose that the
absence of HO-1 interferes with the phenotype of macrophages
(M1 rather than M2) that in turns provokes less IL-15 secretion,
thereby reducing uNK cell numbers (Linzke et al., 2014). HO-1
deficiency resulted not only in fewer uNKs; but also, in shallow SA
remodeling and IUGR (Linzke et al., 2014). The administration
of CO from gestational day 3 until day 8 provoked a significant
increase in the number of uNKs that was independent of IL-15 at
the implantation sites (Linzke et al., 2014). We confirmed that CO
acts directly on uNKs inducing their in situ proliferation (Linzke
et al., 2014). As in other models (Dulak et al., 2002), CO could
positively influence angiogenesis by stimulating the production
of VEGF and PGF, positively influencing the remodeling of the
maternal uterine vascular system (Linzke et al., 2014). It is known
that diminished signaling of VEGF and PGF in the placenta is
aligned with IUGR and pre-eclampsia in humans (Maynard et al.,
2005). Accordingly, there was impaired VEGF, PGF, and IFN-
γ mRNA expression at the fetomaternal interface of Hmox1+/−
and Hmox1−/− implantation sites compared to Wt controls. CO
application to pregnant Hmox1+/− females not only favored the
uNK cell proliferation; but also, enhanced the expression of
VEGF, PGF, and IFN-γ that accompanied SA reshaping (Linzke
et al., 2014). Thus, CO not only protects from an excess of free
heme; but also, positively stimulates uNK proliferation and thus
angiogenesis, both of great importance in the prevention of pre-
eclampsia and IUGR development.
Clark et al. (1998) reported that the placenta secretes a soluble
factor named sFlt-1 that can bind VEGF, thus being its antagonist.
In pre-eclampsia, sFlt-1 is elevated and has since been considered
a marker for pre-eclampsia (Vuorela et al., 2000; Buhimschi et al.,
2005). In Wt mice, neutralization of VEGF-induced proteinuria
(Sugimoto et al., 2003) and sFlt-1 gene transfer provoked pre-
eclampsia-like signs (Maynard et al., 2003; Lu et al., 2007).
Cudmore et al. (2007) showed that, in vitro, the overexpression
of HO-1 in endothelial cells by using a retrovirus-inhibited sFlt-1
release, whereas HO-1 inhibition potentiated sFlt-1 production
from endothelial cells and placental villous explants. Cudmore
et al. (2012) also reported that non-pregnant mice lacking HO-1
produced higher levels of sFlt-1 than Wt mice. However, we were
not able to find any differences in sFlt-1 levels among Hmox1+/+,
Hmox1+/−, and Hmox1−/− female mice during pregnancy (Vilella
et al., 2013). It was reported that CO is able to decrease sFlt-1
release in vitro (Cudmore et al., 2012). In vivo, CO application
has no effect on sFlt-1 levels regardless of the mouse Hmox1
phenotype (Linzke et al., 2014). This was also true for s-Eng,
another pre-eclampsia marker (Linzke et al., 2014). Similarly,
placental sFlt-1 levels in pregnant rats were not affected by HO
inhibition (George et al., 2011). There are other studies in which
CO was able to diminish sFlt-1 levels, but this seems to be inde-
pendent of HO-1. In a mouse model of pre-eclampsia-induced
after sFlt-1 infusion, CO application ameloriated pre-eclampsia
signs (Venditti et al., 2014). However, the doses employed in this
study are very high (250 ppm) and even though the authors
quote this dose as “low,” previous studies showed that at even
lower doses (125 ppm), CO has toxic effects on both the mother
and fetus (El-Mousleh et al., 2012). At 50 ppm, CO was able to
ameliorate the rate of fetal deaths in the abortion-prone mouse
combination CBA/J × DBA/2J and reduce both sFlt-1 and sEng
levels (El-Mousleh et al., 2012).
OUTLOOK: POTENTIAL OF HO-1 AS A THERAPEUTIC TARGET
IN PREGNANCY COMPLICATIONS
CO might be used therapeutically to suppress early and recurrent
onset of spontaneous abortions or fetal deaths associated with
human HMOX1 polymorphisms (Otterbein et al., 2000) or to
prevent IUGR in pre-eclampsia-associated with low HO-1 levels
(Barber et al., 2001). We found that CO can also be used therapeu-
tically to fully reverse IUGR and gestational hypertension when
applied exogenously during late implantation and throughout
placentation. This confirms the great potential of CO for preg-
nancy complications as it is already well known to be protective in
a variety of pathologies (Otterbein et al., 2000; Pamplona et al.,
2007; Motterlini and Otterbein, 2010). Pre-eclampsia, known
to be caused by shallow trophoblast invasion, hence, abnormal
placentation, has not only been linked to HO-1 deficiency, but its
incidence is significantly lower in smokers (England et al., 2003;
Khoury et al., 2004), and as discussed, CO has been proposed
as the main reason for this. Recently, Ahmed proposed to use
the cardiovascular drugs statins (3-hydroxy-3 methyl-glutaryl
coenzyme-A reductase inhibitors) to stimulate HO-1 expression
and inhibit sFlt-1 in pre-eclamptic patients (Ahmed, 2011). In
mice, statins prevented cervical remodeling, myometrial contrac-
tions, and preterm labor in a LPS-induced model of preterm
birth. Interestingly, the protective effects of statins in this model
were associated with increased synthesis, expression, and activity
of HO-1 in the myometrium and cervix. Co-administration of
the HO-1 inhibitor tin protoporphyrin (SnPP) abrogated the
protective effects of statins and preterm births could no longer
been prevented (Gonzalez et al., 2014). These promising results
show the potential of these drugs, but nevertheless careful studies
are required before their universal use (Cleary et al., 2014). In rats,
pravastatin ameloriated hypertension, oxidative stress, and angio-
genic imbalance in a rat model of placental ischemia-induced
hypertension (Bauer et al., 2013). Pravastatin further prevented
the rise in circulating anti-angiogenic factors in a mouse model of
pre-eclampsia. Statins may represent a novel approach to preven-
tion of this devastating disease (Saad et al., 2014). Maternal ther-
apy with pravastatin in mice with sFlt-1-induced pre-eclampsia
could prevent alterations in postnatal growth and metabolic func-
tions in the adult offspring of pre-eclamptic mice (McDonnold
et al., 2014). Similarly, prenatal pravastatin treatment prevented
impairment of fetal programming in mice (Carver et al., 2014).
There is to date one case report from a patient with pre-eclampsia
that was successfully treated with pravastatin (Lefkou et al.,
2014). Because pravastatin and other statins have been shown
to reverse various pathophysiologic pathways associated with
pre-eclampsia, such as angiogenic imbalance, endothelial injury,
inflammation, and oxidative stress, it is claimed to have favorable
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FIGURE 1 | HO-1 catabolizes free heme into biliverdin and releases
CO. This supports the implantation of the fertilized blastocyst. In
the absence of HO-1, excess free heme provokes cell damage
that in turn leads to necrosis and/or apoptosis. This impairs
trophoblast functions, resulting in abnormal placentation, IUGR, and fetal
deaths. These negative consequences of excess free heme could be
prevented in a mouse model by inhalation of low doses of CO
(50 ppm).
safety and pharmacokinetic profiles. National Institute of Child
Health and Human Development Obstetric-Fetal Pharmacology
Research Units Network has started a pilot trial to collect mater-
nal/fetal safety data and to evaluate pravastatin pharmacokinetics
when used as a prophylactic daily treatment in high-risk pregnant
women (identifier NCT01717586, clinicaltrials.gov; Costantine
et al., 2013). The future will show whether these drugs can help
ameliorate pre-eclamptic symptoms and whether HO-1/CO are
involved.
SUMMARY
HO-1 is a unique regulator of reproductive processes in the
female. As depicted in Figure 1, HO-1 supports the implantation
of the fertilized blastocyst and is mediated by its metabolite
CO, which avoids the accumulation of free heme. The on-time
implantation in the presence of HO-1 is followed by a normal
placentation, fetal growth, and well-being. In the absence of
HO-1, excess free heme provokes cell damage and results in
a cascade of events that finally leads to aberrant placentation,
IUGR, and/or fetal loss. These negative consequences of excess
free heme can be prevented by the administration of CO. HO-1
and its metabolite CO both have a great therapeutic potential
in reproductive medicine and reproductive immunology. Further
studies are required to fully understand their mechanisms of
action and how to modulate their levels in situ.
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